Medincell: Completion of Phase 3 Trial for Olanzapine LAI in Schizophrenia by Teva

 

• Medincell to receive a $5 million development milestone payment from Teva with SOLARIS study completion (last patient last visit)
• Richard Malamut, Chief Medical Officer at Medincell comments: “Our partner is advancing the clinical development of the olanzapine LAI with plans for regulatory submission in the US. This structured approach highlights a strong commitment to addressing a critical unmet need. As a result of Medincell technology, a long-acting injectable formulation of olanzapine may be widely used by patients with schizophrenia.”

https://www.businesswire.com/news/home/20250210052066/en/Medincell%C2%A0Completion-of-the-Pivotal-Phase-3-Trial-for-Olanzapine-LAI-in-Schizophrenia-Conducted-by-Teva-Pharmaceuticals